4.6 Article

Longitudinal Progression Trajectory of GFR Among Patients With CKD

期刊

AMERICAN JOURNAL OF KIDNEY DISEASES
卷 59, 期 4, 页码 504-512

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2011.12.009

关键词

Chronic kidney disease; estimated glomerular filtration rate; nonlinear progression; longitudinal cohort study; African American; slope

资金

  1. National Institutes of Health [5U01DK048648, 1R01DK090046-01]
  2. Keryx, Lilly
  3. Pharmanet
  4. Astra Zeneca
  5. Novartis
  6. Reata

向作者/读者索取更多资源

Background: The traditional paradigm of glomerular filtration rate (GFR) progression in patients with chronic kidney disease (CKD) is a steady nearly linear decline over time. We describe individual GFR progression trajectories over 12 years of follow-up in participants in the African American Study of Kidney Disease and Hypertension (AASK). Study Design: Longitudinal observational study. Setting & Participants: 846 AASK patients with at least 3 years of follow-up and 8 GFR estimates. Measurements: Longitudinal GFR estimates from creatinine-based equations. Predictors: Patient demographic and clinical features. Outcomes: Probability of a nonlinear trajectory and probability of a period of nonprogression calculated for each patient from a Bayesian model of individual estimated GFR (eGFR) trajectories. Results: 352 (41.6%) patients showed a >0.9 probability of having either a nonlinear trajectory or a prolonged nonprogression period; in 559 (66.1%), the probability was >0.5. Baseline eGFR >40 mL/min/1.73 m(2) and urine protein-creatinine ratio <0.22 g/g were associated with a higher likelihood of a nonprogression period. 74 patients (8.7%) had both a substantial period of stable or increasing eGFR and a substantial period of rapid eGFR decrease. Limitations: Clinical trial population; absence of direct GFR measurements. Conclusions: In contrast to the traditional paradigm of steady GFR progression over time, many patients with CKD have a nonlinear GFR trajectory or a prolonged period of nonprogression. These findings highlight the possibility that stable kidney disease progression can accelerate and, conversely, provide hope that CKD need not be relentlessly progressive. These results should encourage researchers to identify time-dependent factors associated with periods of nonprogression and other desirable trajectories. Am J Kidney Dis. 59(4):504-512. (C) 2012 by the National Kidney Foundation, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据